A rising trend is observed in patients with atrial fibrillation, supported by the PARAGON-HF trial, which considered a three-fold higher NTproBNP threshold in cases of atrial fibrillation to achieve a comparable risk assessment to that of patients in sinus rhythm [83]. The gene discussed is NPPB; the disease is atrial fibrillation.